Verastem, Inc. (VSTM) Stock Grade

About Verastem, Inc.'s fundamentals

Verastem is a biotechnology company with a market capitalization of $535.1 million that demonstrated exceptional revenue growth of 209.1% year-over-year, indicating rapidly expanding commercial operations or product adoption. However, the company reported a significant net loss in its latest annual statement with a net margin of -677.6%, meaning expenses substantially exceed revenues. The company does not currently pay a dividend, and traditional profitability metrics like P/E ratio and return on equity are not applicable given the loss-making status. This profile is typical of growth-stage biotech firms investing heavily in product development and commercialization while scaling revenues.